Scholars Central

Conference abstractPublished 7 Nov 2016

Validation and characterization of 3xTg (APP/Bin1/COPS5) mice as a new neuropathological model of Alzheimerandprime;s disease

Authors: Ivan Carrera, Ivan Tellado, Lucia Fernandez-Novoa, Carolina Sampedro, Silvia Seoane, Madepalli Lakshmana, Ramon Cacabelos

EuroEspes Biotechnology, Spain EuroEspes Biomedical Research Center, Spain Torrey Pines Institute for Molecular Studies, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In this study, we characterize the neuropathological profile and genetic expression pattern specific for this improved triple transgenic mice (APP/Bin1/COPS5) model of AlzheimerâÂ?Â?s disease (AD) during the first year of life. This novel triple transgenic mouse model over-expresses the Swedish mutation of APP (human amyloid precursor protein) together with Bin1 (bridging integrator 1, AMPH2) and COPS-5 (COP9 constitutive photomorphogenic homolog subunit 5, Jab1), which closely mimics AD human brain pathology. By using histopathological biomarkers and comparative AD gene-expression analysis, we identified an improved neuropathological profile that constitutes a more suitable AD mouse model for neurodegenerative research studies. Results from mice brain histopathological characterization at 3 and 6 months of age show that combined APP, Bin1 and COPS5 expressing genes promote the severity of AD hallmarks in a progressive manner along brain maturation. When compared with simple (APP) or double (APP/PS1) transgenic mice, this triple transgenic mice (APP/Bin1/COPS5), shows significant increase in amyloid-B plaque density at early stages of development (3 months), as well as the associated inflammation hallmarks such as astrogliosis and reactive microglia. These findings support the view that this specific triple gene interaction may generate a powerful degenerative AD mice model, providing new insight into the pathogenesis and molecular/cellular mechanisms driving degenerative neuropathology in AD. This model is a useful tool for assessing the efficacy of therapeutic agents for slowing, preventing or reversing AD progression.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Human Genetics & Embryology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalHuman Genetics & Embryology
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Ivan Carrera”
  • BylineArticles whose byline prints “Ivan Tellado”
  • BylineArticles whose byline prints “Lucia Fernandez-Novoa”
  • BylineArticles whose byline prints “Carolina Sampedro”
  • BylineArticles whose byline prints “Silvia Seoane”
  • BylineArticles whose byline prints “Madepalli Lakshmana”
  • BylineArticles whose byline prints “Ramon Cacabelos”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels